Related references
Note: Only part of the references are listed.Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma
Paul G. Richardson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Risk factors in multiple myeloma: is it time for a revision?
Jill Corre et al.
BLOOD (2021)
Cancer statistics, 2019
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
CD56 Expression Is an Important Prognostic Factor in Multiple Myeloma Even with Bortezomib Induction
Matevz Skerget et al.
ACTA HAEMATOLOGICA (2018)
Low expression of neural cell adhesion molecule, CD56, is associated with low efficacy of bortezomib plus dexamethasone therapy in multiple myeloma
Takashi Yoshida et al.
PLOS ONE (2018)
New Developments in Diagnosis, Prognosis, and Assessment of Response in Multiple Myeloma
Ola Landgren et al.
CLINICAL CANCER RESEARCH (2016)
Absence of both CD56 and CD117 expression on malignant plasma cells is related with a poor prognosis in patients with newly diagnosed multiple myeloma
Ying Pan et al.
LEUKEMIA RESEARCH (2016)
t(14;16)-positive multiple myeloma shows negativity for CD56 expression and unfavorable outcome even in the era of novel drugs
T. Narita et al.
BLOOD CANCER JOURNAL (2015)
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
S. Vincent Rajkumar et al.
LANCET ONCOLOGY (2014)
Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013
Joseph R. Mikhael et al.
MAYO CLINIC PROCEEDINGS (2013)
Clinicopathological correlates of plasma cell CD56 (NCAM) expression in multiple myeloma
Maria Kraj et al.
LEUKEMIA & LYMPHOMA (2008)
Lack of CD56 expression on myeloma cells is not a marker for poor prognosis in patients treated by high-dose chemotherapy and is associated with translocation t(11;14)
M. Hundemer et al.
BONE MARROW TRANSPLANTATION (2007)
Correlation of plasma cell percentages by CD138 immunohistochemistry, cyclin D1 status, and CD56 expression with clinical parameters and overall survival in plasma cell myeloma
Cherie Hilborn Dunphy et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2007)
International uniform response criteria for multiple myeloma
B. G. M. Durie et al.
LEUKEMIA (2006)
Prognostic relevance of CD56 expression in multiple myeloma: A study including 107 cases treated with high-dose melphalan-based chemotherapy and autologous stem cell transplant
H Chang et al.
LEUKEMIA & LYMPHOMA (2006)
Prognostic significance of surface markers expressed in multiple myeloma: CD56 and other antigens
N Sahara et al.
LEUKEMIA & LYMPHOMA (2004)
High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma
JA Child et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Clinicopathological and prognostic characteristics of CD56-negative multiple myeloma
N Sahara et al.
BRITISH JOURNAL OF HAEMATOLOGY (2002)
Expression of CD56/neural cell adhesion molecule correlates with the presence of lytic bone lesions in multiple myeloma and distinguishes myeloma from monoclonal gammopathy of undetermined significance and lymphomas with plasmacytoid differentiation
SA Ely et al.
AMERICAN JOURNAL OF PATHOLOGY (2002)
Share Paper
